



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Domány, et al.

Group Art Unit: Not yet assigned

Serial No.: 10/761,940

Examiner: Not yet assigned

Filed: January 21, 2004

For: Piperidine Derivatives as NMDA Receptor
Antagonists

Attorney Docket No.: 1000546-0003

Assistant Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The Applicants and their attorney are aware of patents, publications or other information that relate to the current application and are cited on the attached PTO Form 1449. In accordance with 37 CFR § 1.97, Applicants hereby submit these forms for the Examiner's consideration.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 122144.

Respectfully submitted,

LORD, BISSELL & BROOK LLP

A handwritten signature in black ink, appearing to read "Matthew O. Brady". The signature is written in a cursive, flowing style. A large, loopy flourish extends from the end of the signature, looping around the text below it.

Matthew O. Brady

Registration No. 44,554

LORD, BISSELL & BROOK LLP

115 South LaSalle Street

Chicago, IL 60603

312-443-0616

Date: February 18, 2004



If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 10

Complete if Known

Application Number	10/761,940
Filing Date	January 21, 2004
First Named Inventor	Gyorgy Domány
Art Unit	n/a
Examiner Name	n/a
Attorney Docket Number	1000546-0003

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	✓ 11	WO97/23214 A1	07-03-1997	Warner-Lambert		
	✓ 12	WO97/23215 A1	07-03-1997	W-L. & Cocensys		
	✓ 13	WO97/23216 A1	07-03-1997	W-L. & Cocensys		
	✓ 14	WO97/23458 A1	07-03-1997	W-L. & Cocensys		
	✓ 15	WO98/18793 A1	05-07-1998	Merck Patent		
	✓ 16	WO99/21539 A1	05-06-1999	Warner-Lambert		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet

3

 Ω'

10

Application Number	10/761,940
Filing Date	January 21, 2004
First Named Inventor	Gyorgy Domány
Art Unit	n/a
Examiner Name	n/a
Attorney Docket Number	1000546-0003

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
✓	17	WO00/00197 A1	01-06-2000	Warner-Lambert		
✓	18	WO00/25109 A1	05-04-2000	Scofield, et al		
✓	19	WO01/30330 A2	05-03-2001	Merck Sharp & D		
✓	20	WO01/32171 A1	05-10-2001	Merck & Co.		
✓	21	WO01/32174 A1	05-10-2001	Merck & Co.		
✓	22	WO01/32177 A1	05-10-2001	Merck & Co.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	4	of	10
-------	---	----	----

Application Number	10/761,940
Filing Date	January 21, 2004
First Named Inventor	Gyorgy Domány
Art Unit	n/a
Examiner Name	n/a
Attorney Docket Number	1000546-0003

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ ~ Number ⁴ ~ Kind Code ⁵ (if known)				
✓	23	WO01/32179 A1	05-10-2001	Merck & Co.		
✓	24	WO01/32615 A1	05-10-2001	Merck et al.		
✓	25	WO01/32634 A1	05-10-2001	Merck & Co.		

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	5	of	10	Application Number	10/761,940
				Filing Date	January 21, 2004
				First Named Inventor	Gyorgy Domány
				Art Unit	n/a
				Examiner Name	n/a
				Attorney Docket Number	1000546-0003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	C4	BARTA, THOMAS, E., et al., Synthesis and Activity of Selective MMP Inhibitors with an Aryl Backbone, Bioorg. Med. Chem. Lett., (2000), pp. 2815-2817, Vol. 10.	
✓	5	BECKETT, A.H., et al., Substituted Oxindoles-I: The Preparation and Spectral Characteristics of Some Simple Oxindole Derivatives, Tetrahedron, (1968), pp.6093-6109, Vol. 24.	
✓	6	BEVERIDGE, S. and HUPPATZ, J.L., The Pschorr Cyclization II, Further Reactions with Pyrrole Derivatives, Aust. J. Chem., (1972), pp. 1341-1346, Vol. 25.	
✓	7	BISAGA, A., and POPIK, P., In Search of a New Pharmacological Treatment for Drug and Alcohol Addition:..., Drug and Alcohol Depend., (2000) pp. 1-15, Vol. 59.	
✓	8	BOSWELL, R.F., et al., Synthesis of Some N-Carboxylic Acid Derivatives of 3-Phenoxypyrrrolidines, J. Med. Chem., (1974), pp. 1000-1008, Vol. 17.	
✓	9	BOYCE, S., et al., Selective NMDA NR2B Antagonists Induce Antinociception Without Motor Dysfunction: Correlation with Restricted Localisation ..., pp. 611-623, Vol. 38.	
✓	10	BUEHLER, C.A., HARRIS, J.O., and ARENDALE, W.F., Reaction of alpha- and gamma-Stilbazoles with Selenium Dioxide, J. Amer. Chem. Soc., (1950), pp. 4953-4955, Vol. 72.	
✓	11	CHAPLEO, C.B., et al., Heteroaromatic Analogues of the •2-Adrenoreceptor Partial Agonist Clonidine, J. Med. Chem., (1989), pp. 1627-1630, Vol. 32.	
✓	12	CHENARD, B.L., and MENNITI, F.S., Antagonists Selective for NMDA Receptors Containing the NR2B Subunit, Curr. Pharm. Des., (1999), pp. 381-404, Vol. 5.	
✓	13	CHIARINO D. and CONTRI, A.M., 2,1-Benzisothiazoline 2,2-Dioxide and Derivatives, J. Heterocycl. Chem., (1986), pp. 1645-1649, Vol. 23.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/761,940
		Filing Date	January 21, 2004
		First Named Inventor	Gyorgy Domány
		Art Unit	n/a
		Examiner Name	n/a
Sheet 6	of 10	Attorney Docket Number	1000546-0003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	14	CLARK, R.L., and PESSOLANO, A.A., Synthesis of Some Substituted Benzimidazolones, J. Amer. Chem. Soc., (1958), pp. 1657-1662, Vol. 80.	
✓	15	CROOK, K.E., and McELVAIN, S.M., Piperidine Derivatives The Phenylpiperidylcarbinols, J. Amer. Chem. Soc., (1930), pp. 4006-4011, Vol. 52.	
✓	16	DESAI, R.D., et al., The Unsaturation and Tautomeric Mobility of Heterocyclic Comps. Part XI. alpha- and beta-Naphthoxazole and...., J. Chem. Soc., (1938), pp. 321-329, Vol. 321.	
✓	17	DI, XIAO, et al., Effect of CP101,606, a Novel NR2B Subunit Antagonist of the N-Methyl-D-Aspartate Receptor, on the Vol. of Isch., Stroke (1997), pp. 2244-2251, Vol. 28.	
✓	18	DICKENS, F., et al., The Formation and Stability of Spiro-Compounds Part VIII. The Diekmann-Komppa Reaction, J. Chem. Soc., (1922), pp. 1496-1507, Vol. 121.	
✓	19	DICKENSON, A. and BESSON, J.M. (Eds.): The Pharmacology of Pain....Excitatory Amino Acid Mechanisms and Their Control, (1997), Springer-Verlag, Berlin.	
✓	20	DOMÁNY et al, New 4-Arylamino piperidines with Antihypoxic and Anticonvulsive Activity, Drug Research, (1994), pp. 989-991, Vol. 44(II), No. 9.	
✓	21	EL KIHIL, A., et al., Reaction of Aminobenzimidazoles with 4-Hydroxy-6-methyl-2-pyrone and 4-Hydroxycoumarine, Synth. Commun., (1999), pp. 2434-2444, Vol. 29.	
✓	22	FADEN, A.I., et al., Effects of Competitive and Non-Competitive NMDA Receptor Antagonists in Spinal Cord Injury, Eur. J. Pharmacol., (1990), pp. 165-174, Vol. 175.	
✓	23	HARTMANN, M., and PANIZZON, L., Über die Darstellung des Amino-isatins und einiger Derivate, Helv. Chim-Acta, (1936), pp. 1326-1333, Vol. 19.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/761,940
		Filing Date	January 21, 2004
		First Named Inventor	Gyorgy Domány
		Art Unit	n/a
		Examiner Name	n/a
Sheet 7	of 10	Attorney Docket Number	1000546-0003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	24	HELSLEY, G.C., et al., Piperidylalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxy piperidyl)ethyl]indoles, J. Med. Chem., (1978), pp. 309-312, Vol. 21.	
✓	25	HERNDON, J.L., et al., Ketanserin Analogues: Structure-Affinity Relationships for 5-HT ₂ and 5-HT _{1C} Serotonin Receptor Binding, J. Med. Chem., (1992), pp. 4903-4910, Vol. 35.	
✓	26	HODGSON, H.H., and MARSDEN, E., Evidence of the isoNitrile and Nitrile Structures of Hantzsch's Aryl syn- and....., J. Chem. Soc., (1944), pp. 1515-1519, Vol. 395.	
✓	27	HONG LI, JIN, et al., Developmental Changes in Localization of NMDA Receptor Subunits in Primary Cultures....., Eur. J. Neuroscience, (1998), pp. 1704-1715, Vol. 10.	
✓	28	HUNSKAAR, S., et al, Formalin Test in Mice, a Useful Technique for Evaluating Mild Analgesics, Journal of Neuroscience Methods, (1985) pp. 69-76, Vol. 14.	
✓	29	IOVU, MIRCEA, et al., Experimental Pharmacodynamic Study of Some New Aminoacetylates and Phenoxyacetylates, Chemical Abstracts, (1982), p. 601, Bucharest, Vol. 33, No. 7.	
✓	30	JACOBSON, P., Ueber Diazosulfide, Liebigs Ann. Chem., (1893), pp. 209-261, Vol. 277.	
✓	31	JAIN, K.K., Evaluation of Memantine for Neuroprotection in Dementia, Expert Opin. Investig. Drugs, (2000), pp. 1397-1406, Vol. 9.	
✓	32	JAMES, A.T., and TURNER, E.E., Structure and Antimalarial Activity, Part IV. Benzinazoles and Mercaptodihydroglyoxalines, J. Chem. Soc., (1950), pp. 1515-1519.	
✓	33	JOHNSON, M.I., and BUNGE, R.P., Primary Cell Cultures of Peripheral....., In: Protocols for Neural Cell Culture, eds: Fedoroff, S.; Richardson A., (1992), pp. 51-75, Chap. 4.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 8 of 10	Application Number	10/761,940
	Filing Date	January 21, 2004
	First Named Inventor	Gyorgy Domány
	Art Unit	n/a
	Examiner Name	n/a
		Attorney Docket Number 1000546-0003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	34	KAO, J.P.Y., Practical Aspects of Measuring [Ca ²⁺] with Fluorescent Indicators, Meth. Cell. Biol., (1994), pp. 155-181, Vol. 40.	
✓	35	KATZ, L and COHEN, M.S., Benzoxazole Derivatives. I. 2-Mercaptobenzoxazoles, J. Org. Chem., (1954), pp. 758-766, Vol. 19.	
✓	36	KAUFMANN, H.P., Arzneimittelsynthetische Studien IX: Benzthiazolylharnstoffe (Mitbearbeitet von P. Schulz), Arch. Pharm., (1935), p. 31-53, Vol. 13.	
✓	37	LIPTON, STUART A., Neuronal Injury Associated with HIV-1: Approaches to Treatment, Annu. Rev. Pharmacol. Toxicol., (1998), pp. 159-177, Vol. 38.	
✓	38	LUTFY, KABIRULLAH, et al., Inhibition of Murphine Tolerance by NMDA Receptor Antagonists in the Formalin Test, Brain Res., (1996), pp. 171-181, Vol. 731.	
✓	39	MANABE, Y., et al., Enhanced Fos Expression in Rat Lumbar Spinal Cord Cultured with Cerebrospinal Fluid From Patents....., Neurol. Res., (1999), pp. 309-312, Vol. 21.	
✓	40	MERCER, L.D., et al., I-Ifenprodil: Synthesis and Characterization of Binding to a Polyamine-Sensitive Site....., J. Neurochem., (1993), pp. 120-126, Vol. 61.	
✓	41	MONGE, A., et al., Synthesis of New Oxazolidine, Oxazolidin-2-one and Perhydro-1,4-oxazine Derivatives of, J. Heterocycl. Chem., (1995), pp. 1429-1438, Vol. 32.	
✓	42	MUTEL, V., et al., In Vitro Binding Properties in Rat Brain of [3H]RO 25-6981, a Potent and Selective Antagonist of NMDA....., J. Neurochem., (1998), pp. 2147-2155, Vol. 70.	
✓	43	OKIYAMA, K., et al., Effects of the NMDA Antagonist CP-98-113 on Regional Cerebral Edema and Cardiovascular, ..., Brain Res., (1998), pp. 291-298, Vol. 792.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/761,940
		Filing Date	January 21, 2004
		First Named Inventor	Gyorgy Domány
		Art Unit	n/a
		Examiner Name	n/a
Sheet 9	of 10	Attorney Docket Number	1000546-0003

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	44	PARSONS, W., DANYSZ, W. and QUACK, G., Glutamate in CNS Disorders as a Target for Drug Development: An Update, Drug News Perspect., (1998), pp. 523-569, Vol. 11.	
✓	45	PEREZ, M., et al., Synthesis, Binding Affinity and Intrinsic Activity of New Anilide Derivatives of Serotonin at Human 5-HT1D..., Eur. J. Med. Chem., (1997), 129-134, Vol. 32.	
✓	46	RAJAPPA, S. and SHENOY, S.J., Quinone-imides: Regiospecificity of Nucleophilic Attack on N-alkanesulphonyl-N1-alkanoyl 1,..., Tetrahedron, (1986), pp. 5739-5746, Vol. 42.	
✓	47	REINERT, M.M. and BULLOCK, R., Clinical Trials in Head Injury, Neurol. Res., (1999), pp. 330-338, Vol. 21.	
✓	48	ROTHMAN, S.M. and OLNEY, J.W., Excitotoxicity and the NMDA Receptor, TINS, (1987), pp. 299-302, Vol. 10.	
✓	49	SAJIKI, H., Selective Inhibition of Benzyl Ether Hydrogenolysis with Pd/C Due to the Presence of Ammonia, Pyridine ..., Tetrahedron Lett., (1995), pp. 3465-3468, Vol. 36.	
✓	50	SAM, J., RICHMOND, C.W., and VALENTINE, J.L., 3-Aminoalkyl-2-benzoxazolinones, J. Med. Chem., (1967), pp. 408-410, Vol. 10.	
✓	51	SATO, YASUNOBU, et al., Syntheses and pharmacology of 1-[2-(hydroxyethoxy)ethyl]-4-(p-chlorobenzyl) piperidine hydrochloride (piclobetol)...., Heterocycles (1972), 34266w.	
✓	52	SHRIDHAR, D.R., et al., Potential Diuretics: Part I-Synthesis of Some Substituted 2,4-Dihydro-1-oxo/thioxo[1,2,4]triazolo..., Indian J. Chem., (1984), pp. 1279-1283, Vol. 23B.	
✓	53	SHRIDHAR, D.R., et al., Synthesis & Anthelmintic Activity of Some New 6- & 7-Isothiocyanato-2H-1,4-benzoxa(thia)...., Indian J. Chem., (1985), pp. 1263-1267, Vol. 24B.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	10	of	10	Application Number	10/761,940
				Filing Date	January 21, 2004
				First Named Inventor	Gyorgy Domány
				Art Unit	n/a
				Examiner Name	n/a
				Attorney Docket Number	1000546-0003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	54	SINGH, A.K., and KANVAH, S., Photophysical Studies of Substituted 1,2-diarylethenes: twisted Intramolecular....., J. Chem. Soc. Perkin Trans., (2001), pp. 395-401, Vol. 2.	
✓	55	STEECE-COLLIER, K., et al., Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-D-....., Exp. Neurol., (2000), pp. 239-243, Vol. 163.	
✓	56	TCHANI, G., et al., Evaluation of Inhibitory Calcic Activity of a Series of Diethylbenzylphosphonates, Eur. J. Med. Chem., (1992), pp. 845-850, Vol. 27.	
✓	57	TOMITA, MASATSUGU, and MINAMI, SHINSAKU, The Schmidt Reaction with Benzocycloalkenones, J. Chem. Soc., (1969), pp. 183-188, Vol. 196.	
✓	58	TURSKI, L., et al., Muscle Relaxant and Anticonvulsant Activity of 3-(")-2-carboxypiperazin-4-yl)-propyl-1-phosphonic....., Neurosci. Lett., (1987), pp. 143-148, Vol. 73.	
✓	59	WARRENER, R.N., et al., A Concise, Regio and Stereoselective Route to Fluorinated Protoberberines via Tandem Addition-....., Tetrahedron, (1998), pp. 7485-7496, Vol. 54.	
✓	60	WEISSMAN, S.A., et al., Efficient Synthesis of N-Arylpiperazinones via a Selective Intramolecular Mitsunobu Cyclodehydration Tetrahedron Lett., (1998), pp. 7459-7462, Vol. 39.	
✓	61	WHEELER, A.S., and SMITH, S.C., Direct Conversion of Derivatives of Dichloro-acetic Acid into Derivatives of....., J. Amer. Chem. Soc., (1923), pp. 1994-1999, Vol. 45.	
✓	62	WOO BAE, J., et al., Chemoselective Reduction of Nitroaromatics to Anilines Using Decaborane in Methanol, Tetrahedron Lett., (2000), pp. 175-177, Vol. 41.	
✓	63	ZHOU, ZHANG-LIN and KEANA, J.F.W., A Practical Synthesis of 4-(Substituted-benzyl)piperidines and (")-3-(Substituted-benzyl)...., J. Org. Chem., (1999), pp. 3763-3766, Vol. 64.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.